All In Biotech

Drug Trial Radar · NCT04632108

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

199

Actual

Start

Jan 28, 2021

Primary completion

Oct 31, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
Collaborators
Jiangsu Aosaikang Biopharmaceutical Co., Ltd
First posted
Nov 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors. Patients with gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer are preferred.

Conditions

  • Malignant Solid Tumor

Interventions

  • ASKB589 InjectionDrug

    ASKB589 Injection with dose escalation stage of 0.3mg/kg up to 20mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with serious adverse events (SAE) as assessed by CTCAE v5.0Time frame: up to 21 days following last dose
  2. The incidence and case number of DLT (Dose Limiting Toxicity) during observation periodTime frame: up to 21 or 28 days following first dose
  3. Number of participants with adverse events as assessed by CTCAE v5.0Time frame: up to 21 days following last dose
  4. Maximum Tolerated Dose (MTD)Time frame: up to 21 or 28 days following first dose
  5. The recommended doseTime frame: from date of treatment start until data cut-off, up to 2 years
  6. Objective response rateTime frame: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing cancer hospital

    Beijing, Beijing Municipality, China

  • Linyi cancer hospital

    Linyi, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.